Neovacs SA (EPA: ALNEV) has received a positive data review from the Independent Data and Safety Monitoring Board (IDSMB) for the ongoing Phase IIb clinical trial of IFNalpha Kinoid in lupus, the French biotech company announced on Tuesday.
In its review -- the third IDSMB data review of the ongoing Phase IIb clinical trial -- the board looked at cumulative data, focusing on the safety data.